“Evaluating Triplet Regimens for Advanced Biliary Tract Cancer: A
Meta-analysis of Safety and Efficacy Profiles”
Abstract
Objective: Biliary Tract Cancer (BTC) is a significant health
concern with limited resectable cases. This meta-analysis assessed the
safety of triplet regimens for advanced BTC, specifically gemcitabine,
cisplatin, nab-paclitaxel, and gemcitabine, oxaliplatin, erlotinib,
along with their associated adverse events. Method: Following
PRISMA guidelines, we systematically reviewed PubMed/Medline, Google
Scholar, and the Cochrane Library from inception to November 2022.
Results: Our analysis of 5 studies favored
Gem+Cisplatin+nab-Paclitaxel over GEMOX-T in terms of safety and adverse
events. Qualitative analysis of 7 studies (491 patients) showed that
Gem+Cisplatin+nab-Paclitaxel also outperformed in median overall
survival, progression-free survival, and response rates.
Conclusion: This study suggests that
Gem+Cisplatin+nab-Paclitaxel is a safer and more effective treatment
than GEMOX-T for advanced BTC. It exhibits superior outcomes in terms of
survival and response rates. Further research should focus on optimizing
treatment regimens to reduce adverse effects in advanced BTC patients.